Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa)

This is an investigator-initiated, single-center clinical trial evaluating the efficacy and safety of ALK inhibitors in patients with locally advanced or metastatic bone cancer harboring truncated ALK (ALKATI) alterations. Eligible patients must have disease progression after standard therapy or no suitable standard treatment options. Participants will receive either crizotinib (Xalkori®) or alectinib (Alecensa®), with treatment selection determined by the study investigators. The study aims to assess antitumor activity, safety, and clinical outcomes in this rare molecular subtype of bone cancer.

NCT Number	NCT07560410
Lead Sponsor	China Medical University Hospital
Conditions	Bone Cancer
Enrollment	10 participants
Start Date	2026-05-15
Primary Completion	2029-01-15 (estimated)
Study Completion	2029-04-14 (estimated)
Updated on ClinicalTrials.gov	2026-05-11